Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …

Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …

Background and Aims Activation of the antitumor immune response using programmed
death receptor‐1 (PD‐1) blockade showed benefit only in a fraction of patients with …

Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …

Importance For more than a decade, sorafenib has been the only systemic treatment option
for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over …

Advanced hepatocellular carcinoma (HCC) is a serious therapeutic challenge and targeted
therapies only provide a modest benefit in terms of overall survival. Novel approaches are …

Liver cancer ranks the sixth in cancer incidence and the second in tumor related mortality
worldwide, with over half of the new cases and deaths occur in China. Because of difficulties …

Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for
advanced hepatocellular carcinoma (HCC) but provides limited survival benefits. Recently …